Equities

Themis Medicare Ltd

THEMISMED:NSI

Themis Medicare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)285.60
  • Today's Change27.60 / 10.70%
  • Shares traded1.13m
  • 1 Year change+64.80%
  • Beta1.2201
Data delayed at least 15 minutes, as of Sep 20 2024 11:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Themis Medicare Ltd's net income fell -23.51% from 569.01m to 435.24m despite revenues that grew 7.74% from 3.54bn to 3.82bn. An increase in the selling, general and administrative costs as a percentage of sales from 37.12% to 41.14% was a component in the falling net income despite rising revenues.
Gross margin63.51%
Net profit margin12.26%
Operating margin11.59%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, cash reserves at Themis Medicare Ltd fell by 26.25m. However, the company earned 220.94m from its operations for a Cash Flow Margin of 5.79%. In addition the company used 159.48m on investing activities and also paid 87.70m in financing cash flows.
Cash flow per share6.69
Price/Cash flow per share38.57
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Themis Medicare Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -23.53%.
Div yield(5 year avg)0.69%
Div growth rate (5 year)--
Payout ratio (TTM)9.20%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-13.22
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.